At some point the shorts should start to cover on the pending Medidur data. The same investigator for the Duke study, Dr. Jaffe, is doing the first PIII trial for Uveitis. It should be very good data indeed. The MHRA might just approve Medidur in the EU on the basis of this data. After all, the EU has seen the drug (Iluvien) work for DME and is well tolerated. Good luck guys.
Oh, except for Retisert.....(it does however create some IOP issues). Durasert/Medidur however has volumes better side effect profile than the FDA approved Retisert. So, with data pending next month, the momentum should continue for EU approval. Remember, with Iluvien already approved in the EU, Medidur should be granted approval for the Uveitis indication. Something to watch for.
It's an increase of 275K over the month prior. I guess some are betting on IOP being unmanageable in the first of the PIII uveitis trials along with bad efficacy. I don't see it. So, will they cover in the last week before data is announced? Just saying....
Hey guys......This is an expiration of the mixed shelf 3 years ago. They expire and have to be renewed. Been cleared with IR. pSivida has ample cash as everyone knows. No worries.
Frank, The warrants would be exercisable "if" the stock reaches $5 by that date in January of 16'. That's good for those who purchased the stock and warrants; when pSivida was doing a financing. If the stock does not reach the $5 mark they are not exercisable. Anyone else can chime in on this too.
Picked this off the Web......I think this was a Q&A to pSivida IR....Beverly.
Currently there are 1.176 million warrants out with a weighted price of $3.67 – they are broken down in terms of 552,500 warrants from a financing in January 2011 that are exercisable at $5 and expire in January 2016 and the warrants from the August financing.
Terry, It's been very good news for Iluvien lately. So why the market attitude? It appears as though the sentiment is negative, while the efficacy news couldn't be better. Could there be a need for a capital raise soon? Perhaps. They spent some significant money this year while not generating much. The stars seem to be lining up, let's hope the need for capital doesn't set Alimera back too much and the J code gets the ball rolling. Sure won't hurt pSivida getting a little cash in from US sales. GL.
Good question and a bit out of my league here. A question more suited to IR or management. I haven't even heard of the specific drugs yet. I'm just sure they're off patent, because that's the way pSivida works. Interesting that in the CC, Paul referred to toxicity of the PDGF's. I'm assuming that the Durasert platform handles it as it uses 10,000 times "less drug", according to Paul ...
Road less traveled for sure. It's OK, I have a very full life. Little southwest golf vacation this week. I hope to survive it, then, I'll be right back here , like a needle in your side.
One more dip in the pool of epic stupidity for the "blowboy". Hope you sold and you can just #$%$ as usual . Medidur data out by the end of the year. You can help us celebrate.
Kool, I'm sure you recall that the primary investigator for the first PIII Medidur trial is Dr. Jaffe of Duke University. He is also the Doc that just presented the outstanding results of the three year study ( PII study). The Jaffe study had the varied patients, vs. the patients in the PIII Medidur trial, there should be similar efficacy and tolerance profiles. Things are really looking good for Medidur. The platform in general, to carry small molecules......like the repurposed cancer drugs also sound very encouraging. The stock will eventually head north for all the right reasons. GL
He's building a company Moron, with 3 year sustained release platforms. Anyone else on the planet doing that? What a fricken' goof.
Just like it happened with Iluvien, pSivida's own drug for Uveitis will get EU approval on the basis on the one "FRICKEN STELLAR" trial data now being evaluated. There are "NO" approved drugs for posterior Uveitis.....on the planet. So, with population in dire need of such a therapy, Medidur will start looking pretty good and very soon. Why else would the MHRA and pSivida be meeting? The "Data" will speak for itself, and it's coming before the end of the year. Ashton keeps talking about a 175K patient population, well, that's just in the US. And, if the data shows anything close to the PII Duke study data, in terms of recurrence of the disease and visual acuity improvement, this will be the posterior Uveitis drug of "CHOICE" globally. So, if the EU and US patient population is 300K patients.......do the math at $8500/ a unit. Yep.....that would be Billions for a company with a MC of 115 Million.
Wow. So NOT going to happen. If you didn't listen to the CC , and I'm sure you didn't because you don't do DD, then you missed a whole list of potential catalyst that will soon propel the company. Just because you lost a $100 bucks from pulling the sell trigger does not make it the fault of longs on this MB.